Unfortunately, systemic LXR activation concurrently promotes hepatic de novo lipogenesis, hepatic steatosis, and hypertriglyceridemia via direct activation of the SREBP-1c and fatty acids (FAs) synthesis pathways, resulting in a rise in VLDL TG29,32,33. Here, SREBF1 is linked to hypertriglyceridemia.